{"title":"Positioning the liver at the centre of fructose-associated extrahepatic cancer","authors":"Thomas Marjot","doi":"10.1016/j.jhep.2025.02.021","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>The consumption of fructose, typically as sucrose or high-fructose corn syrup, has exploded over the last few decades. Nutritional survey data collected in North America between the 1970s and 2000s indicate that the contribution of fructose to daily calorie intake has increased by over 25% across all demographics including adolescents and children.<sup>1</sup> This trend coincides with an exponential rise in the prevalence of metabolic diseases including obesity, metabolic dysfunction-associated steatotic</section></section><section><section><h2>Objectives, methods and findings</h2>This body of work involved a variety of techniques including the use of stable isotopes to trace the fate of dietary fructose in mice and to characterise its impact on the growth of implanted tumour cells. The authors then aimed to identify the circulating mediators of tumour behaviour using a combination of untargeted metabolomics and co-culture experiments between hepatocytes and cancer cell lines.Firstly, fructose supplementation was found to promote tumour growth across a range of zebra</section></section><section><section><h2>Significance of findings</h2>Dietary fructose represents a shared risk factor for MASLD and extrahepatic cancers. The negative impact of fructose on the liver appears to be mediated by a number of pathogenic pathways including increased visceral adiposity, insulin resistance, and hepatic <em>de novo</em> lipogenesis (DNL). These effects are not entirely related to overnutrition, with calorie-matched clinical studies showing greater deterioration in metabolic parameters with high-fructose compared to high-glucose diets.<sup>13</sup><sup>,</sup><sup>14</sup> As is</section></section><section><section><h2>Financial support</h2>T.M. is supported by a <span>National Institute for Health Research</span> (NIHR) Academic Clinical Lectureship. The views expressed are those of the author and not necessarily those of the <span>National Health Service</span> (NHS), the NIHR or the Department of Health.</section></section><section><section><h2>Conflict of interest</h2>T.M. has no conflicts of interest to declare.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"78 2 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.02.021","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Section snippets
Background and context
The consumption of fructose, typically as sucrose or high-fructose corn syrup, has exploded over the last few decades. Nutritional survey data collected in North America between the 1970s and 2000s indicate that the contribution of fructose to daily calorie intake has increased by over 25% across all demographics including adolescents and children.1 This trend coincides with an exponential rise in the prevalence of metabolic diseases including obesity, metabolic dysfunction-associated steatotic
Objectives, methods and findings
This body of work involved a variety of techniques including the use of stable isotopes to trace the fate of dietary fructose in mice and to characterise its impact on the growth of implanted tumour cells. The authors then aimed to identify the circulating mediators of tumour behaviour using a combination of untargeted metabolomics and co-culture experiments between hepatocytes and cancer cell lines.Firstly, fructose supplementation was found to promote tumour growth across a range of zebra
Significance of findings
Dietary fructose represents a shared risk factor for MASLD and extrahepatic cancers. The negative impact of fructose on the liver appears to be mediated by a number of pathogenic pathways including increased visceral adiposity, insulin resistance, and hepatic de novo lipogenesis (DNL). These effects are not entirely related to overnutrition, with calorie-matched clinical studies showing greater deterioration in metabolic parameters with high-fructose compared to high-glucose diets.13,14 As is
Financial support
T.M. is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship. The views expressed are those of the author and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.
Conflict of interest
T.M. has no conflicts of interest to declare.Please refer to the accompanying ICMJE disclosure forms for further details.
期刊介绍:
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.